This can be explained by the fact that Idasanutlin is a direct inhibitor of MDM2 and that both SEM and ALL-PO carry p53 mutations, resulting in conformational changes, the loss of its tumor suppressor functions, and conveying oncogenic gain-of-function activities. This evidence concerns the gene TP53 and neoplasm.